Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
This report studies the eosinophilic esophagitis drug market.
The classification of eosinophilic esophagitis drug includes budesonide, fluticasone and other types, and the proportion of budesonide in 2017 is about 52%.
North America is the largest consumption region of eosinophilic esophagitis drug, with a sales market share nearly 32% in 2017. Europe is the second largest consumption region of eosinophilic esophagitis drug, enjoying Sales market share nearly 29% in 2017.
Market competition is intense. AstraZeneca, GSK, Bayer are the leaders of the industry, and they hold key technologies and patents, with high-end customers: have been formed in the monopoly position in the industry.
According to this study, over the next five years the Eosinophilic Esophagitis Drug market will register a 6.2% CAGR in terms of revenue, the global market size will reach US$ 150 million by 2024, from US$ 100 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Eosinophilic Esophagitis Drug business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Esophagitis Drug market by product type, application, key manufacturers and key regions and countries.
This study considers the Eosinophilic Esophagitis Drug value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3: and forecast to 2024 in section 11.7.
Budesonide
Fluticasone
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 11.8.
Hospitals
Clinics
Drugstore
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AstraZeneca
GSK
Bayer
Adare Pharmaceuticals
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Shire
Calypso
Celgene
Regeneron
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Eosinophilic Esophagitis Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Eosinophilic Esophagitis Drug market by identifying its various subsegments.
Focuses on the key global Eosinophilic Esophagitis Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Eosinophilic Esophagitis Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Eosinophilic Esophagitis Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
